

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p align="center">Licensee</p> <p>1. Munson Healthcare Grayling Hospital</p> <p>2. 1100 East Michigan Avenue Grayling, MI 49738</p>	<p>In accordance with letter dated June 2, 2015, received June 19, 2015,</p> <p>3. License number 21-16489-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date October 31, 2021</p> <p>5. Docket No. 030-11125 Reference No.</p>	
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Iodine-125 permitted by 10 CFR 35.400</p> <p>D. Palladium-103 permitted by 10 CFR 35.400</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Sealed sources (Bard Brachytherapy, Inc. Model STM 1251)</p> <p>D. Sealed sources (Theragenics Corporation Model TheraSeed® 200)</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>C. 200 millicuries</p> <p>D. 1 curie</p>

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. and D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 1100 East Michigan Avenue, Grayling, Michigan.
11. The Radiation Safety Officer (RSO) for this license is **Dennis J. Aurand, M.S.**
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

21-16489-01

Docket or Reference Number

030-11125

Amendment No. 28

B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

David Keith Heimbarger, M.D.

10 CFR 35.400.

C. David Phelps, Jr., M.D.**10 CFR 35.100 and 35.200.**

Michael E. Schulte, M.D.

10 CFR 35.200.

David K. MacIntosh, D.O.

10 CFR 35.200.

John N. Beattie, M.D.

10 CFR 35.200.

Thomas W. Crosby, M.D.

10 CFR 35.200.

John Andrew Varner, D.O.

10 CFR 35.200.

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated May 17, 2011;

B. Letters dated September 29, 2011, January 23, 2012, December 15, 2014, and June 2, 2015, (received June 19, 2015, with attachment); and,


C. Letter received April 9, 2015.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date

JUL 24 2015

By


Colleen Carol Casey
Materials Licensing Branch
Region III